Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ:ADXS opened at $0.11 on Monday. The firm has a market cap of $4.48 million, a price-to-earnings ratio of -0.01 and a beta of 1.81. The firm has a fifty day moving average price of $0.05 and a 200 day moving average price of $0.12. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.